Radiometallated receptor-avid peptide conjugates for specific in vivo targeting of cancer cells

Nuclear Medicine and Biology

Volumn 28, Issue 5, 2001, Pages 527-539

  Hoffman, T J ^a,b   Quinn, T P ^a   Volkert, W A ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cancer; GC C receptors; GRP receptors; Peptide conjugates; Receptor avid tracers; MSH receptors

Indexed keywords

ALPHA INTERMEDIN DERIVATIVE; ALPHA INTERMEDIN RECEPTOR; ALPHA INTERMEDIN[4 NORLEUCINE 7 DEXTRO PHENYLALANINE 3 TYROSINE] I 125; ALPHA INTERMEDIN[4 NORLEUCINE 7 DEXTRO PHENYLALANINE]; BOMBESIN DADT TC 99M; BOMBESIN DERIVATIVE; BOMBESIN IN 111; BOMBESIN PENTETATE IN 111; BOMBESIN[8-14] RH 105; BOMBESIN[8-14] TC 99M; CELL RECEPTOR; CYCLIC ALPHA INTERMEDIN RE 188; CYCLIC ALPHA INTERMEDIN TC 99M; DEPREOTIDE TC 99M; GASTRIN RELEASING PEPTIDE RECEPTOR; GUANYLATE CYCLASE C RECEPTOR; MERCAPTOACETYLGLYCYLGLYCINE TC 99M; N SUCCINIMIDYL 3 IODOBENZOATE I 125; N SUCCINIMIDYL 4 FLUOROBENZOATE F 18; OMEGA AMINOCAPROIC ACID 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID ESCHERICHIA COLI HEAT STABLE PEPTIDE INDIUM IN 111; PENTETREOTIDE; PENTETREOTIDE IN 111; PEPTIDE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TETRATHIAMACROCYCLIC BOMBESIN[7-14] RH 105; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CANCER; CANCER CELL; CANCER SCINTISCANNING; CANCER THERAPY; CONJUGATE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; IMAGE ANALYSIS; IN VIVO STUDY; MELANOMA; NONHUMAN; PROTEIN EXPRESSION; TUMOR;

ANIMALS; GUANYLATE CYCLASE; HUMANS; MELANOMA; NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTORS, BOMBESIN; RECEPTORS, CELL SURFACE; RECEPTORS, PEPTIDE; RECEPTORS, PITUITARY HORMONE;

EID: 0034976943     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(01)00209-8     Document Type: Article

References (100)

1. Radiometal-labeled agents (non-technetium) for diagnostic imaging
2. Systematic treatments for advanced cutaneous melanoma
3. Strategies to reduce renal radioactivity levels of antibody fragments
4. 111In]-DTPA-labeled analogues of alpha-melanocyte stimulating hormone for melanoma targeting: Receptor binding in vitro and in vivo
5. Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues
6. Evaluation of diaminedithiol-based bifunctional chelate for labeling small molecules with Tc-99m
7. [Indium-111-DTPA-D-Phe-1] octreotide, a potential radiopharmaeutical for imaging somatostin receptor positive tumors: Synthesis, radiolabeling and in vivo validation
8. A chelating derivative of α-melanocyte stimulating hormone as a potential imaging agent for malignant melanoma
9. Improved prospects for cancer therapy with radiolabeled antibody fragments and peptides?
10. Selective drug delivery by means of receptor-mediated endocytosis
11. A multicenter trial with somatostatin analog (99m)Tc depreotide in the evaluation of solitary pulmonary nodules
12. 4] bombesin, a new radioligand for bombesin-receptor scintigraphy
13. Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy
14. Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extaintestinal tissues
15. Escherichia coli heat-stable toxin receptors in human colonic tumors
16. 99mTc-labeled cyclic alpha-melanocyte stimulating hormone peptide analog
17. 188Re-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting
18. Guanylin in RNA expression in human intestine and colorectal adenocarcinoma
19. Receptors for Eschrichia coli heat stable enterotoxin in human intestine and in a human intestinal cell line (CaCO-2)
20. Pharmacokinetics and biodistribution of genetically-engineered antibodies
21. Systematic development of bombesin/gastrin-releasing peptide antagonists
22. Identification of two affinity states of low affinity receptors for Escherchia coli heat-stable enterotoxin: Correlation of occupation of lower affinity state with guanylate cyclase activation
23. 3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy
24. 3]octreotide, a promising somatostatin analogue for radionuclide therapy
25. 3]octreotide: Peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy
26. The family of guanylyl cyclase receptors and their ligands
27. Radiolabeling with Tc-99m to study high-capacity and low-capacity biochemical systems
28. The design of site-directed radiopharmaceuticals for use in drug discovery
29. Guanylin regulatory peptides: Structures, biological activities mediated by cyclic GMP and pathobiology
30. Guanylin peptides: Renal actions mediated by cyclic GMP
31. Structure and functional analysis of G protein-coupled receptors and potential diagnostic ligands
32. 2 conjugate for specific targeting of tumors expressing gastrin releasing peptide receptors (GRP-R)
33. Enhanced binding and inertness to dehalogenation of α-melanotropic peptides labeled using N-succinimidyl 3-iodobenzoate
34. Escherichia coli heat-stable enterotoxins, guanylins, and their receptors: What are they and what do they do?
35. Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination
36. Radioiodinated endothelin-1: A radiotracer for imaging endothelin receptor distribution and occupancy
37. Nuclear medicine imaging of lung cancer
38. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system
39. Regulation of intestinal uroguanylin/guanylin receptor-mediated responses by mucosal acidity
40. Drug analysis based on signaling responses to G-Protein-coupled receptors
41. 105Rh labeled bombesin analogues: Enhancement of GRP receptor binding affinity utilizing aliphatic carbon chain linkers
42. Evaluation of radiolabelled (I-125 vs. Rh-105) bombesin analogue internalization in normal and tumor cell lines
43. Iodinated bombesin analogs: Effect of a N-terminal vs. side chain iodine attachment of BBN/GRP receptor binding
44. 99mTc-GRP receptor targeting peptides using multiamino acid linking groups
45. Technetium-99m-labeled receptor-specific small-molecule radiopharmaceuticals: Recent developments and encouraging results
46. Factors influencing the in vivo pharmacokinetics of peptides and antibody fragments: The pharmacokinetics of two PET-labeled low molecular weight proteins
47. Bombesin receptor antagonist: Different classes and cellular basis of action
48. 125I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide: A high affinity Φ-receptor ligand for potential imaging of breast cancer
49. 99mTc-labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine-based bifunctional chelating agent
50. Design and development of new hydroxymethyl phosphine based bifunctional chelating agents (BfCAs) for use in radiopharmaceutical applications
51. Distribution of heat-stable enterotoxin/guanylin receptors in the intestinal tract of man and other mammals
52. 3]-octreotide: The Rotterdam experience with more than 1,000 patients
53. Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide
54. Somatostatin receptor imaging of neuroendocrine carcinomas: Implications for patient management and radiotherapy
55. 2 and N-terminal aromatic residues
56. 99mTc-Diaminedithiol analog of bombesin
57. Technetium-99m chelate-containing receptor-binding peptides
58. Pharmacokinetic considerations in the development of peptide-based imaging agents
59. Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma
60. Gastrin-releasing peptide receptors in the human prostate: Relation to neoplastic transformation
61. Chelate radiochemistry: Cleavable linkers lead to altered levels of radioactivity in the liver
62. Intraperitoneal radioimmunotherapy of ovarian cancer with Lutetium-177-CC-49
63. Bombesin-like peptides in small cell lung cancer: Biochemical characterization and secretion from a cell line
64. Review - Peptides and growth factors in non-small cell lung cancer
65. Immunological factors in human sarcomas and melanomas: A rational basis for immunotherapy
66. Synthesis solution structure, binding activity, and cGMP activity of human guanylin and its disulfide isomer
67. Cellular processing of Copper-67-labeled monoclonal antibody chCE7 by human neuroblastoma cells
68. Internalization and degradation of monoclonal antibody chCE7 by human neuroblastoma cells
69. DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy
70. Molecular structure of the toxic domain of heat-stable enterotoxin produced by a pathogenic strain of Escherichia coli
71. Radiolabeled antibody therapy of lymphomas
72. Inhibitory effect of bombesin receptor antagonist Rc-3095 on the growth of human pancreatic cancer cells in vivo and in vitro
73. Effects of linker chemistry on the pharmacokinetics of radioimmunoconjugates
74. Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analogue (RC-160) on growth of HT-29 human colon cancers in nude mice
75. Neuropeptide receptors in health and disease: The molecular basis for in vivo imaging
76. Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy
77. Synthesis of bombesin analogues for radiolabeling with rhenium-188
78. 7]á-melanocyte stimulating hormone: A highly potent α-melanotropin with ultralong biological activity
79. α-Melanocyte stimulating hormone message and inhibitory sequences: Comparative structure-activity studies on melanocytes
80. Successful imaging of malignant melanoma with technetium-99m-labeled monoclonal antibodies
81. Vehicles, chelators, and radionuclides: Choosing the "building blocks" of an effective therapeutic radioimmunoconjugate
82. Guanylyl cyclase in a heat-stable enterotoxin receptor
83. Guanylin: Where it's at! Why's it there?
84. Radionuclide imaging of neuroendocrine tumors: Biological basis and diagnostic results
85. Radioimmunotherapy of micrometastases: Sidestepping the solid-tumor hurdle
86. Improving monoclonal antibody pharmacokinetics via chemical modification
87. Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells
88. 3S-chelation system for the preparation of Tc-99m and Re-188 labeled biomolecules
89. Effect of bombesin, GRP (14-27) and bombesin/GRP receptor antagonist Rc-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters
90. Specific receptors for alpha-melanocyte-stimulating hormone are widely distributed in tissues of rodents
91. 7]-alpha-MSH, an alpha-melanocyte stimulating hormone analogue
92. 99mTc-RP 527, a gastrin releasing peptide (GRP) analogue for visualization of GRP receptor expressing malignancies: A feasibility study
93. 111In-DOTA-ST conjugate
94. Design and development of receptor-avid peptide conjugates for in vivo targeting of cancer
95. Therapeutic radiopharmaceuticals
96. Radiohalogenation of proteins: An overview of radionuclides, labeling methods, and reagents for conjugate labeling
97. 7]α-MSH in B16 melanoma cells
98. The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of malignant melanoma